Navidea Biopharmaceuticals Inc Net debt/EBITDA
Quel est le Net debt/EBITDA de Navidea Biopharmaceuticals Inc?
Le Net debt/EBITDA de Navidea Biopharmaceuticals Inc est 0.38
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur NYSEMKT par rapport à Navidea Biopharmaceuticals Inc
Que fait Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Entreprises avec net debt/ebitda similaire à Navidea Biopharmaceuticals Inc
- Kühne + Nagel International AG a Net debt/EBITDA de 0.37
- Enphase a Net debt/EBITDA de 0.38
- Global Technologies a Net debt/EBITDA de 0.38
- RoodMicrotec N.V a Net debt/EBITDA de 0.38
- VentriPoint Diagnostics a Net debt/EBITDA de 0.38
- AM Resources a Net debt/EBITDA de 0.38
- Navidea Biopharmaceuticals Inc a Net debt/EBITDA de 0.38
- Caledonia Investments Plc a Net debt/EBITDA de 0.38
- Tymlez a Net debt/EBITDA de 0.38
- Synovus a Net debt/EBITDA de 0.39
- Eskay Mining a Net debt/EBITDA de 0.39
- Foxconn Interconnect Technology a Net debt/EBITDA de 0.39
- DermTech a Net debt/EBITDA de 0.39